NCT03872947: A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

NCT03872947
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: PD-L1
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Chemotherapy, Therapeutic Antibody, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Skin
Additional Notes: Patients must either be 1) eligible for PD1 Inhibitor (nivolumab or pembrolizumab) or 2) have at least one palpable subcutaneous malignant lesion
Exclusions: 
https://ClinicalTrials.gov/show/NCT03872947

Comments are closed.

Up ↑